Last reviewed · How we verify
bevacizumab, carboplatin and paclitaxel — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
bevacizumab, carboplatin and paclitaxel (bevacizumab, carboplatin and paclitaxel) — Grupo de Investigación y Divulgación Oncológica.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| bevacizumab, carboplatin and paclitaxel TARGET | bevacizumab, carboplatin and paclitaxel | Grupo de Investigación y Divulgación Oncológica | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- bevacizumab, carboplatin and paclitaxel CI watch — RSS
- bevacizumab, carboplatin and paclitaxel CI watch — Atom
- bevacizumab, carboplatin and paclitaxel CI watch — JSON
- bevacizumab, carboplatin and paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). bevacizumab, carboplatin and paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-carboplatin-and-paclitaxel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab